About 34,900 results
Open links in new tab
  1. Tardive Dyskinesia (TD) | AUSTEDO XR® (deutetrabenazine ...

    AUSTEDO XR ® (deutetrabenazine) extended-release tablets and AUSTEDO ® (deutetrabenazine) tablets are indicated in adults for the treatment of chorea associated with …

  2. AUSTEDO XR® Medication for Tardive Dyskinesia (TD)

    Once-daily AUSTEDO XR® (deutetrabenazine) extended release tablets reduce uncontrollable Tardive Dyskinesia (TD) body movements. See safety info including Boxed Warning.

  3. Austedo (deutetrabenazine): Uses, Side Effects, Dosage Guide

    Aug 20, 2025 · Austedo's drug class is a VMAT2 inhibitor (vesicular monoamine transporter 2 inhibitor). Austedo tablets are taken twice daily, and the Austedo XR (extended-release) …

  4. Patients Taking AUSTEDO XR® (deutetrabenazine)

    Sep 21, 2025 · The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis …

  5. Austedo Phase 4 Data Shows Reduction in Tardive Dyskinesia ...

    Nov 12, 2025 · Austedo standard and XR tablets are currently indicated for adults for the treatment of chorea in Huntington disease and tardive dyskinesia. Austedo is the first VMAT2 …

  6. Austedo: Regaining Control Over Uncontrolled Movements in ...

    Jul 16, 2024 · Austedo (aw-STED-oh) was approved in 2017 and is the first medicine approved to treat both tardive dyskinesia and chorea caused by Huntington’s disease.

  7. Teva Announces AUSTEDO® XR (deutetrabenazine) Extended ...

    May 29, 2024 · U.S. FDA approves new one pill, once-daily AUSTEDO XR tablets (30, 36, 42, 48 mg/day) AUSTEDO XR offers more flexibility with the most once-daily doses of any vesicular …

  8. AUSTEDO XR and AUSTEDO may cause parkinsonism in patients with Huntington’s disease or tardive dyskinesia. Parkinsonism has also been observed with other VMAT2 inhibitors.

  9. AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR ...

    Nov 7, 2025 · The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and …

  10. Dosing & Getting Started - Tardive Dyskinesia (TD) | AUSTEDO ...

    AUSTEDO XR ® (deutetrabenazine) extended-release tablets and AUSTEDO ® current Prescribing Information. Parsippany, NJ: Teva Neuroscience, Inc. 2. Hauser RA, Barkay H, …